{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:57:37Z","timestamp":1792267057502,"version":"4.4.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.mayocp.2013.09.003","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T04:38:48Z","timestamp":1383107928000},"page":"1294-1311","source":"Crossref","is-referenced-by-count":89,"title":["Lipoprotein(a), Cardiovascular Disease, and Contemporary Management"],"prefix":"10.1016","volume":"88","author":[{"given":"Terry A.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocp.2013.09.003_bib1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archinte.168.6.598","article-title":"Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data","volume":"168","author":"Bennet","year":"2008","journal-title":"Arch Intern Med"},{"issue":"22","key":"10.1016\/j.mayocp.2013.09.003_bib2","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.mayocp.2013.09.003_bib3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.296.11.1363","article-title":"Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women","volume":"296","author":"Suk Danik","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2013.09.003_bib4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1399-0004.1997.tb04342.x","article-title":"Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study","volume":"52","author":"Berg","year":"1997","journal-title":"Clin Genet"},{"issue":"3","key":"10.1016\/j.mayocp.2013.09.003_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A\u00a0new serum type system in man\u2013the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"6","key":"10.1016\/j.mayocp.2013.09.003_bib6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1172\/JCI109813","article-title":"Turnover of lipoprotein (a) in man","volume":"65","author":"Krempler","year":"1980","journal-title":"J\u00a0Clin Invest"},{"issue":"22","key":"10.1016\/j.mayocp.2013.09.003_bib7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMp038128","article-title":"Lp(a) lipoprotein\u2014coping with heterogeneity","volume":"349","author":"Scanu","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2013.09.003_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1874241601003010072","article-title":"Variation of Lp(a) plasma concentrations in health and disease","volume":"3","author":"Siekmeier","year":"2010","journal-title":"Open Clin Chem J"},{"issue":"6","key":"10.1016\/j.mayocp.2013.09.003_bib9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2362.2001.00811.x","article-title":"Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney","volume":"31","author":"Frank","year":"2001","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2013.09.003_bib11","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0022-2275(20)37461-7","article-title":"Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans","volume":"37","author":"Marcovina","year":"1996","journal-title":"J\u00a0Lipid Res"},{"issue":"6","key":"10.1016\/j.mayocp.2013.09.003_bib12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF00201550","article-title":"Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups","volume":"86","author":"Sandholzer","year":"1991","journal-title":"Hum Genet"},{"issue":"9","key":"10.1016\/j.mayocp.2013.09.003_bib13","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1161\/ATVBAHA.107.141291","article-title":"A\u00a0polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease","volume":"27","author":"Luke","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"17","key":"10.1016\/j.mayocp.2013.09.003_bib14","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1074\/jbc.272.17.11079","article-title":"Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase: generation of mini-Lp(a) particles and apo(a) fragments","volume":"272","author":"Edelstein","year":"1997","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2796.2000.00628.x","article-title":"LPA gene: interaction between the apolipoprotein(a) size ('kringle IV' repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level","volume":"247","author":"R\u00f8sby","year":"2000","journal-title":"J\u00a0Intern Med"},{"issue":"26","key":"10.1016\/j.mayocp.2013.09.003_bib16","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2013.09.003_bib17","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1371\/journal.pgen.0020107","article-title":"Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study","volume":"2","author":"Clarke","year":"2006","journal-title":"PLoS Genet"},{"issue":"6","key":"10.1016\/j.mayocp.2013.09.003_bib18","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1194\/jlr.M012526","article-title":"Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study","volume":"52","author":"Lamon-Fava","year":"2011","journal-title":"J\u00a0Lipid Res"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/CIRCGENETICS.110.958371","article-title":"Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study","volume":"4","author":"Hopewell","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib20","doi-asserted-by":"crossref","first-page":"e14581","DOI":"10.1371\/journal.pone.0014581","article-title":"Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans","volume":"6","author":"Deo","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.mayocp.2013.09.003_bib21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2013.09.003_bib23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.mayocp.2013.09.003_bib25","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa001066","article-title":"Lp(a) lipoprotein, vascular disease, and mortality in the elderly","volume":"349","author":"Ariyo","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0735-1097(00)01126-8","article-title":"Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk","volume":"37","author":"von Eckardstein","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.mayocp.2013.09.003_bib27","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.mayocp.2013.09.003_bib28","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.ATV.20.12.2619","article-title":"High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men","volume":"20","author":"Paultre","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/01.CIR.62.2.249","article-title":"Apolipoprotein A-I, A-II and C- II in black and white residents of Evans County","volume":"62","author":"Tyroler","year":"1980","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mayocp.2013.09.003_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0026-0495(79)90070-2","article-title":"Black-white differences in plasma lipoproteins in Cincinnati schoolchildren (one-to-one pair matched by total plasma cholesterol, sex, and age)","volume":"28","author":"Morrison","year":"1979","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.CIR.54.2.309","article-title":"Serum lipoprotein profile in children from a biracial community: the Bogalusa Heart Study","volume":"54","author":"Srinivasan","year":"1976","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.ATV.17.2.239","article-title":"A\u00a0prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants","volume":"17","author":"Wild","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"16","key":"10.1016\/j.mayocp.2013.09.003_bib33","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/eurheartj\/ehi222","article-title":"Lipoprotein(a) and coronary heart disease among women: beyond a cholesterol carrier?","volume":"26","author":"Shai","year":"2005","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.mayocp.2013.09.003_bib34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mayocp.2013.09.003_bib35","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0021-9150(91)90007-P","article-title":"Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants","volume":"89","author":"Jauhiainen","year":"1991","journal-title":"Atherosclerosis"},{"issue":"22","key":"10.1016\/j.mayocp.2013.09.003_bib37","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.1995.03530220037029","article-title":"Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)","volume":"274","author":"Maher","year":"1995","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.mayocp.2013.09.003_bib38","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocp.2013.09.003_bib39","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2013.09.003_bib40","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2013.09.003_bib41","unstructured":"MRC\/Cancer Research UK\/BHF Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Clinical Medicine, Medical Sciences Division, Oxford University. HPS2-THRIVE: Preliminary results. January 2013. University of Oxford CTSU website. http:\/\/www.ctsu.ox.ac.uk\/hps2-thrive\/index.htm. Updated May 2, 2013. Accessed September 15,\u00a02013."},{"issue":"23","key":"10.1016\/j.mayocp.2013.09.003_bib42","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.mayocp.2013.09.003_bib43","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.mayocp.2013.09.003_bib44","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.mayocp.2013.09.003_bib45","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","article-title":"Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)","volume":"101","author":"Ballantyne","year":"2008","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijcard.2011.12.103","article-title":"Lipid-altering efficacy and safety profile of co-administered extended release niacin\/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia","volume":"167","author":"Chen","year":"2013","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jacl.2008.02.004","article-title":"Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study","volume":"2","author":"Ballantyne","year":"2008","journal-title":"J\u00a0Clin Lipidol"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacl.2009.02.009","article-title":"Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: the SUPREME Study","volume":"3","author":"Insull","year":"2009","journal-title":"J\u00a0Clin Lipidol"},{"issue":"12","key":"10.1016\/j.mayocp.2013.09.003_bib49","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia","volume":"62","author":"Maccubbin","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00129784-200808020-00001","article-title":"Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study","volume":"8","author":"Karas","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"10.1016\/j.mayocp.2013.09.003_bib51","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0002-9149(03)00318-7","article-title":"Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels","volume":"91","author":"Capuzzi","year":"2003","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.mayocp.2013.09.003_bib52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","author":"Kashyap","year":"2002","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.mayocp.2013.09.003_bib53","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.mayocp.2013.09.003_bib54","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"issue":"12A","key":"10.1016\/j.mayocp.2013.09.003_bib55","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A\u00a0new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2013.09.003_bib56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107424849600100302","article-title":"Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial","volume":"1","author":"Morgan","year":"1996","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"issue":"12A","key":"10.1016\/j.mayocp.2013.09.003_bib57","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0021-9150(93)90102-Z","article-title":"The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover","volume":"101","author":"Seed","year":"1993","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.mayocp.2013.09.003_bib59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J\u00a0Intern Med"},{"issue":"12A","key":"10.1016\/j.mayocp.2013.09.003_bib60","doi-asserted-by":"crossref","first-page":"35U","DOI":"10.1016\/S0002-9149(98)00952-7","article-title":"Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study","volume":"82","author":"Goldberg","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib61","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.mayocp.2013.09.003_bib62","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0955-2863(02)00284-X","article-title":"Niacin and cholesterol: role in cardiovascular disease (review)","volume":"14","author":"Ganji","year":"2003","journal-title":"J\u00a0Nutr Biochem"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib63","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.CIR.95.2.329","article-title":"Lipoprotein(a) as a determinant of coronary heart disease in young women","volume":"95","author":"Orth-Gom\u00e9r","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.mayocp.2013.09.003_bib64","unstructured":"US Preventive Services Task Force. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Clinical Summary of US Preventive Services Task Force Recommendation. AHRQ Publication No. 12-05168-EF-4. http:\/\/www.uspreventiveservicestaskforce.org\/uspstf12\/menohrt\/menohrtsum.htm. Published October 2012. Accessed September 15,\u00a02013."},{"issue":"7","key":"10.1016\/j.mayocp.2013.09.003_bib65","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.mayocp.2013.09.003_bib66","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1161\/hc0802.104280","article-title":"Subgroup interactions in the Heart and Estrogen\/Progestin Replacement Study: lessons learned","volume":"105","author":"Furberg","year":"2002","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.mayocp.2013.09.003_bib67","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.mayocp.2013.09.003_bib68","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.288.7.872","article-title":"Postmenopausal hormone replacement therapy: scientific review","volume":"288","author":"Nelson","year":"2002","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.mayocp.2013.09.003_bib69","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.283.14.1845","article-title":"Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause","volume":"283","author":"Shlipak","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.mayocp.2013.09.003_bib71","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0002-9149(94)90279-8","article-title":"Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis","volume":"73","author":"Daida","year":"1994","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2013.09.003_bib72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1744-9987.1997.tb00147.x","article-title":"Clinical application and effectiveness of low-density lipoprotein apheresis in the treatment of coronary artery disease","volume":"1","author":"Daida","year":"1997","journal-title":"Ther Apher"},{"issue":"10","key":"10.1016\/j.mayocp.2013.09.003_bib73","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1194\/jlr.M008961","article-title":"Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy","volume":"51","author":"Nicholls","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.mayocp.2013.09.003_bib74","doi-asserted-by":"crossref","unstructured":"Albers JJ, Slee A, O'Brien K, et\u00a0al. Relationship of apolipoproteins A-1 and B, and lipoprotein (a) to cardiovascular outcomes in the AIM-HIGH trial [published online ahead of print August 7, 2013]. J Am Coll Cardiol. http:\/\/dx.doi.org\/10.1016\/j.jacc.2013.06.051.","DOI":"10.1016\/j.jacc.2013.06.051"},{"issue":"4","key":"10.1016\/j.mayocp.2013.09.003_bib75","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression","volume":"61","author":"Lavigne","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.mayocp.2013.09.003_bib76","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jacc.2013.01.082","article-title":"Niacin therapy lives for another day\u2014maybe? [letter]","volume":"61","author":"Lavie","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3, suppl","key":"10.1016\/j.mayocp.2013.09.003_bib77","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jacl.2011.04.001","article-title":"Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Ito","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"issue":"4","key":"10.1016\/j.mayocp.2013.09.003_bib78","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jacl.2010.07.002","article-title":"Management of Lp(a)","volume":"4","author":"Brown","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.mayocp.2013.09.003_bib79","unstructured":"Helfand M, Buckley D, Fleming C, et\u00a0al. Screening for Intermediate Risk Factors for Coronary Heart Disease: Systematic Evidence Synthesis. Evidence Syntheses, No. 73, 2009. AHQR Publication No. 10-05141-EF-1. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK35208. Accessed September 15,\u00a02013."},{"issue":"7","key":"10.1016\/j.mayocp.2013.09.003_bib80","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-151-7-200910060-00008","article-title":"Using nontraditional risk factors in coronary heart disease risk assessment: US Preventive Services Task Force recommendation statement","volume":"151","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib81","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"issue":"11","key":"10.1016\/j.mayocp.2013.09.003_bib82","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.mayocp.2013.09.003_bib84","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/CIRCGENETICS.111.959601","article-title":"Genetic variants in the apolipoprotein(a) gene and coronary heart disease","volume":"4","author":"Li","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib85","first-page":"179","article-title":"Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met\u00a0allele in the Atherosclerosis Risk in Communities (ARIC) study","volume":"102","author":"Shiffman","year":"2009","journal-title":"Thromb Haemost"},{"issue":"13","key":"10.1016\/j.mayocp.2013.09.003_bib86","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A\u00a0randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2013.09.003_bib87","series-title":"Handbook of Lipoprotein Testing","first-page":"345","article-title":"Lipoprotein (a): structure, measurement and clinical significance","author":"Marcovina","year":"2000"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib88","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0022-2275(20)40123-3","article-title":"Quantification of cholesterol in all lipoprotein classes by the VAP-II method","volume":"35","author":"Kulkarni","year":"1994","journal-title":"J\u00a0Lipid Res"},{"issue":"3","key":"10.1016\/j.mayocp.2013.09.003_bib89","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/clinchem\/23.3.536","article-title":"Beta-lipoprotein cholesterol quantitation with polycations","volume":"23","author":"Heuck","year":"1977","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib90","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.mayocp.2013.09.003_bib91","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.mayocp.2013.09.003_bib92","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/01.CIR.96.5.1390","article-title":"Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women","volume":"96","author":"Nguyen","year":"1997","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2013.09.003_bib93","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacl.2012.01.004","article-title":"Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups","volume":"6","author":"Konerman","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"issue":"16, suppl S","key":"10.1016\/j.mayocp.2013.09.003_bib94","first-page":"818","article-title":"Lipoprotein(a) cholesterol, but not Lp(a) mass, is an independent predictor of angiographic coronary artery disease and subsequent cardiovascular events in patients referred for coronary angiography","volume":"116","author":"McConnell","year":"2007","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.mayocp.2013.09.003_bib95","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.mayocp.2013.09.003_bib96","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mayocp.2013.09.003_bib97","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.mayocp.2013.09.003_bib98","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/clpt.2011.271","article-title":"Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction","volume":"91","author":"Gutstein","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2013.09.003_bib99","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1194\/jlr.M018010","article-title":"Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib","volume":"53","author":"Krauss","year":"2012","journal-title":"J\u00a0Lipid Res"},{"issue":"9603","key":"10.1016\/j.mayocp.2013.09.003_bib100","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies","volume":"370","author":"Krishna","year":"2007","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.mayocp.2013.09.003_bib101","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2013.09.003_bib102","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ahj.2009.07.028","article-title":"Design of the DEFINE trial: Determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib","volume":"158","author":"Cannon","year":"2009","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.mayocp.2013.09.003_bib103","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N\u00a0Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619613007957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619613007957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T23:10:44Z","timestamp":1646953844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619613007957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":103,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0025619613007957"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2013.09.003","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}